OverviewSuggest Edit

Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Listed on London’s AIM since 2005 (AIM: SLN), and with operations in London and Berlin, Silence is one of very few listed companies globally with human validated RNA delivery systems. Its AtuRNAi® technology is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. It has been used in three Phase 2 clinical trials, two awaiting results. Delivery capability is key for the next stage in genetic medicine, targeting disease right at the cause. Silence has an expanding early stage pipeline and collaborates with world leading research institutions to develop the most promising drug candidates. For more information, visit us at www.silence-therapeutics.com, or follow us on Twitter - @SilenceTheraPlc
TypePublic
Founded1999
HQLondon, GB
Websitesilence-therapeutics.com

Latest Updates

Employees (est.) (Jul 2021)615(+847%)
Job Openings2
Revenue (FY, 2017)£16 K(-97%)
Share Price (Nov 2021)£5.6(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Silence Therapeutics

Mark Rothera

Mark Rothera

President and Chief Executive Officer, Executive Director
Iain Ross

Iain Ross

Non-Executive Chairman
Craig Tooman

Craig Tooman

Chief Financial Officer
James Ede-Golightly

James Ede-Golightly

Non-Executive Director
Alistair Gray

Alistair Gray

Senior Independent Non-Executive Director
Giles Campion

Giles Campion

EVP, Head of R&D and Chief Medical Officer
Show more

Silence Therapeutics Office Locations

Silence Therapeutics has offices in London, Hoboken, New York and Berlin
London, GB (HQ)
72 Hammersmith Rd
London, GB
27 Eastcastle St, Fitzrovia
Berlin, DE
Robert-Rössle-Straße 10
Hoboken, NJ, US
221 River St 9th floor
New York, NY, US
434 W 33rd St #814
Show all (5)

Silence Therapeutics Financials and Metrics

Silence Therapeutics Revenue

Silence Therapeutics's revenue was reported to be £16 k in FY, 2017
GBP

Net income (FY, 2018)

(18.4m)

EBITDA (FY, 2018)

(20.2m)

EBIT (FY, 2018)

(20.6m)

Market capitalization (10-Nov-2021)

497.1m

Closing stock price (10-Nov-2021)

5.6

Cash (31-Dec-2018)

21.5m
Silence Therapeutics's current market capitalization is £497.1 m.
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

210.1k1.4m959.0k138.0k1.2m1.3m159.0k509.0k1.9m4.0m2.2m1.7m2.4m693.6k163.0k117.0k15.0k770.0k16.0k

Revenue growth, %

(87%)

Cost of goods sold

986.1k1.8m1.7m3.0m3.0m2.5m2.5m3.0m1.7m1.7m3.2m4.8m6.7m5.1m5.8m3.4m3.4m

Gross profit

(1.5m)(1.7m)(2.0m)(2.4m)(1.3m)(1.7m)(1.5m)(1.1m)(1.2m)(796.0k)(4.5m)(3.4m)(3.5m)(2.7m)(3.2m)
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

6.7m5.2m3.7m10.5m11.4m9.1m7.2m5.1m2.6m9.1m8.8m10.2m3.4m1.1m3.6m3.7m8.9m15.9m16.9m51.9m39.0m42.7m21.5m

Accounts Receivable

210.1k29.0k838.0k879.0k159.0k168.0k201.0k692.0k164.9k598.0k35.9k2.0k375.0k1.6m810.0k

Inventories

82.0k27.4k

Current Assets

6.7m5.2m3.9m10.8m12.0m9.6m8.4m6.4m3.2m9.7m9.6m11.6m4.4m1.8m4.4m3.9m9.1m21.3m22.2m53.6m42.0m45.5m29.5m
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(965.5k)(1.8m)(1.6m)(2.1m)(1.9m)(2.2m)(1.5m)(2.3m)(2.8m)(3.6m)(3.8m)(5.1m)(7.4m)(7.5m)(8.8m)(5.7m)(26.3m)(9.0m)(11.1m)(6.6m)(8.4m)(1.6m)(18.4m)

Cash From Operating Activities

1.0m1.9m2.1m1.2m3.4m3.1m2.4m2.5m2.7m2.8m4.0m3.8m(7.0m)(4.6m)(10.6m)(5.1m)(4.9m)(6.8m)(9.5m)(8.3m)(10.1m)(9.6m)(16.8m)

Cash From Financing Activities

6.3m5.6k289.0k8.0m3.9m8.0m(95.0k)9.5m3.5m5.2m3.8k2.7m12.4m5.5m10.2m18.8m10.8m39.2m(101.0k)48.0k341.0k

Net Change in Cash

5.5m1.5m1.5m685.0k87.0k772.0k6.1m2.1m2.2m6.5m267.0k1.4m(7.0m)(2.2m)2.4m165.1k5.2m6.9m1.2m35.2m(14.8m)3.5m(21.2m)
GBPFY, 1996

Financial Leverage

1.1 x
Show all financial metrics

Silence Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Silence Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Silence Therapeutics Online and Social Media Presence

Embed Graph

Silence Therapeutics News and Updates

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

Silence Therapeutics to Host R&D Day on October 21, 2021

Silence Therapeutics to Host R&D Day on October 21, 2021

Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development

Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
Show more

Silence Therapeutics Frequently Asked Questions

  • When was Silence Therapeutics founded?

    Silence Therapeutics was founded in 1999.

  • Who are Silence Therapeutics key executives?

    Silence Therapeutics's key executives are Mark Rothera, Iain Ross and Craig Tooman.

  • How many employees does Silence Therapeutics have?

    Silence Therapeutics has 615 employees.

  • Who are Silence Therapeutics competitors?

    Competitors of Silence Therapeutics include Clemson Eye, Applied BioCode and AltheaDx.

  • Where is Silence Therapeutics headquarters?

    Silence Therapeutics headquarters is located at 72 Hammersmith Rd, London.

  • Where are Silence Therapeutics offices?

    Silence Therapeutics has offices in London, Hoboken, New York and Berlin.

  • How many offices does Silence Therapeutics have?

    Silence Therapeutics has 5 offices.